Autoantibodies and Biomarker Discovery

    Research output: Chapter in Book/Report/Conference proceedingChapter

    1 Citation (Scopus)

    Abstract

    There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.

    Original languageEnglish (US)
    Title of host publicationProteomic and Metabolomic Approaches to Biomarker Discovery
    PublisherElsevier Inc.
    Pages363-378
    Number of pages16
    ISBN (Print)9780123944467
    DOIs
    StatePublished - Jun 2013

    Fingerprint

    Biomarkers
    Autoantibodies
    Antigens
    Peptoids
    Display devices
    Cell Fractionation
    Protein Array Analysis
    Bacteriophages
    Autoantigens
    Fractionation
    Medical problems
    Nervous System Diseases
    Proteomics
    Proteins
    Complementary DNA
    Tissue
    Peptides
    Mutation
    Antibodies
    Neoplasms

    Keywords

    • Autoantibodies
    • Autoimmunity
    • Biomarker
    • Diabetes
    • Tumor antigen

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Qiu, J., & Anderson, K. (2013). Autoantibodies and Biomarker Discovery. In Proteomic and Metabolomic Approaches to Biomarker Discovery (pp. 363-378). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394446-7.00023-6

    Autoantibodies and Biomarker Discovery. / Qiu, Ji; Anderson, Karen.

    Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc., 2013. p. 363-378.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Qiu, J & Anderson, K 2013, Autoantibodies and Biomarker Discovery. in Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc., pp. 363-378. https://doi.org/10.1016/B978-0-12-394446-7.00023-6
    Qiu J, Anderson K. Autoantibodies and Biomarker Discovery. In Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc. 2013. p. 363-378 https://doi.org/10.1016/B978-0-12-394446-7.00023-6
    Qiu, Ji ; Anderson, Karen. / Autoantibodies and Biomarker Discovery. Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc., 2013. pp. 363-378
    @inbook{8dd37698941147978aa4e35f69a14f78,
    title = "Autoantibodies and Biomarker Discovery",
    abstract = "There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.",
    keywords = "Autoantibodies, Autoimmunity, Biomarker, Diabetes, Tumor antigen",
    author = "Ji Qiu and Karen Anderson",
    year = "2013",
    month = "6",
    doi = "10.1016/B978-0-12-394446-7.00023-6",
    language = "English (US)",
    isbn = "9780123944467",
    pages = "363--378",
    booktitle = "Proteomic and Metabolomic Approaches to Biomarker Discovery",
    publisher = "Elsevier Inc.",

    }

    TY - CHAP

    T1 - Autoantibodies and Biomarker Discovery

    AU - Qiu, Ji

    AU - Anderson, Karen

    PY - 2013/6

    Y1 - 2013/6

    N2 - There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.

    AB - There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.

    KW - Autoantibodies

    KW - Autoimmunity

    KW - Biomarker

    KW - Diabetes

    KW - Tumor antigen

    UR - http://www.scopus.com/inward/record.url?scp=84902040616&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84902040616&partnerID=8YFLogxK

    U2 - 10.1016/B978-0-12-394446-7.00023-6

    DO - 10.1016/B978-0-12-394446-7.00023-6

    M3 - Chapter

    SN - 9780123944467

    SP - 363

    EP - 378

    BT - Proteomic and Metabolomic Approaches to Biomarker Discovery

    PB - Elsevier Inc.

    ER -